REPL · Replimune Group, Inc.
$5.35
-3.28 (-38.01%)
At close · Jul 28
Going-concern doubt
— flagged Jun 29, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-K filed Jun 29, 2026
Market Cap
$449.11M
Shares
83.95M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.35
Open$6.60
Day$5.14–6.62
52W$1.50–12.50
Avg vol 30d4.0M
Short int23.7M · 28.2% float · 9.4d
Short vol33%
Last earningsMay 22, 2025
DataJan 2020–Jul 2026
Filing10-K · Jun 29
Up next
FQ2-27 quarter ends
~Sep 30, 2026
Est
filed Jun 29, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
−41%
below
RSI (14)
24
oversold
MACD trend
Negative
52-week position
35%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−54%
trailing
6-month return
−23%
trailing
YTD return
−45%
this year
Relative strength
−31%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Distributing
36 of 187 funds reported for Jun 30 · net -165.7K sh shares · +17 new
Insider flow
Distributing
Net -$585.0K over 90 days · 100% sells
Short interest
Falling
28.18% of float · ▼ -0.1% MoM · 9.4 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
187 holders — near 3-yr high, broad support
Squeeze score
70
high risk · 0–100
Fundamentals
EPS growth
−10%
Y/Y
Free cash flow
$-282.6M
Balance sheet
$125.7M
net cash
Quant / Vol
risk profile
Volatility
218%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
21.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
−41%
Bearish
RSI (14)
24
Neutral
MACD trend
Negative
Bearish
52-week position
35%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Distributing
36 of 187 funds reported for Jun 30 · net -165.7K sh shares · +17 new
Insider flow
Distributing
Net -$585.0K over 90 days · 100% sells
Short interest
Falling
28.18% of float · ▼ -0.1% MoM · 9.4 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
187 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $5 · 35%
52-wk high $13
vs 200-day avg -31%
vs 50-day avg -41%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
REPL
this stock
Replimune Group, Inc.
|
$449.11M | -45.0% | — | — | 28.2% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +8.2% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -9.8% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| REPL | -49.1% | -54.0% | -23.3% | -51.7% | -45.0% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -48.1% | -54.0% | -30.7% | -50.9% | -53.6% |
Key facts
CIK
1737953
CUSIP
76029N106
13F (30d)
31 filings
31 filers
Visit website
Investor relations